Published in Rev Urol on January 01, 2004
Duloxetine for the treatment of post-prostatectomy stress urinary incontinence. Can Urol Assoc J (2013) 0.82
Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med (2000) 4.33
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos (2003) 1.98
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology (2001) 1.88
Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther (1995) 1.77
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther (2003) 1.66
Neural control of the lower urinary tract. Int J Urol (1997) 1.46
Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol (2001) 1.41
Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology (2003) 1.40
Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol (2000) 1.23
Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol (1994) 1.21
Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology (2003) 1.17
Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci (2002) 1.14
Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol (2003) 1.12
Serotoninergic, noradrenergic, and peptidergic innervation of Onuf's nucleus of normal and transected spinal cords of baboons (Papio papio). J Comp Neurol (1992) 1.04
Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol (2002) 1.03
Oestrogens and lower urinary tract function. Maturitas (2000) 1.01
Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int (2003) 0.95
Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.88
Estrogen and urinary incontinence in women. Maturitas (1994) 0.88
Duloxetine Eli Lilly & Co. Curr Opin Investig Drugs (2000) 0.86
Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.80
Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol (1999) 0.80
Conservative treatment of female stress incontinence with imipramine. J Urol (1984) 0.79
Phenylpropanolamine and other OTC alpha-adrenergic agonists. Med Lett Drugs Ther (2000) 0.77
Role of 5-HT receptors in treatment of overactive bladder. Drugs Today (Barc) (2003) 0.77
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol (2010) 2.68
Artificial urinary sphincter revision: the role of ultrasound. Urology (2013) 2.62
Contemporary management of postprostatectomy incontinence. Eur Urol (2011) 2.01
An artificial somatic-central nervous system-autonomic reflex pathway for controllable micturition after spinal cord injury: preliminary results in 15 patients. J Urol (2003) 1.73
Managing the urethra at transvaginal pelvic organ prolapse repair: a urodynamic approach. J Urol (2008) 1.67
Urodynamic studies in adults: AUA/SUFU guideline. J Urol (2012) 1.51
Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol (2005) 1.49
Artificial urinary sphincter versus male sling for post-prostatectomy incontinence--what do patients choose? J Urol (2009) 1.30
American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. Urology (2003) 1.30
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn (2013) 1.17
Comparison of diagnostic criteria for female bladder outlet obstruction. J Urol (2006) 1.14
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc (2008) 1.11
Review article: Mid-urethral synthetic slings for female stress urinary incontinence. BJU Int (2010) 1.10
Female urethral reconstruction. Urol Clin North Am (2011) 1.01
Female stress urinary incontinence: how do patient and physician perspectives correlate in assessment of outcomes? Curr Opin Urol (2006) 0.99
The male perineal sling: assessment and prediction of outcome. J Urol (2007) 0.95
Surgical management of Skene's gland abscess/infection: a contemporary series. Int Urogynecol J (2011) 0.95
Effect of tension-free vaginal tape and TVT-obturator on lower urinary tract symptoms other than stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.94
A urodynamics protocol to optimally assess men with post-prostatectomy incontinence. Neurourol Urodyn (2005) 0.90
Primary bladder neck obstruction in men and women. Rev Urol (2005) 0.90
Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol (2006) 0.90
Urinary incontinence. Prim Care (2010) 0.88
Pubovaginal sling and pelvic prolapse repair in women with occult stress urinary incontinence: effect on postoperative emptying and voiding symptoms. Urology (2002) 0.87
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder. Int Urogynecol J (2014) 0.87
Treatment of post-prostatectomy incontinence with male slings in patients with impaired detrusor contractility on urodynamics and/or who perform Valsalva voiding. J Urol (2011) 0.87
Patient perception of videourodynamic testing: a questionnaire based study. J Urol (2005) 0.86
Clinical impact of overactive bladder. Rev Urol (2002) 0.85
Midurethral slings for all stress incontinence: a urology perspective. Urol Clin North Am (2012) 0.85
Management of recurrent urinary tract infections in healthy adult women. Rev Urol (2013) 0.84
Repeat urethrolysis after failed urethrolysis for iatrogenic obstruction. J Urol (2003) 0.84
Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol (2009) 0.84
Degree of bother caused by nocturia in women. Neurourol Urodyn (2004) 0.83
Management of obstructive voiding dysfunction after incontinence surgery: lessons learned. Urology (2003) 0.83
Outcomes of patients lost to followup after mid urethral synthetic slings--successes or failures? J Urol (2010) 0.81
Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.81
Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int (2005) 0.81
Primary bladder neck obstruction in men, women, and children. Curr Urol Rep (2007) 0.80
Recent advances in management of female lower urinary tract trauma. Curr Opin Urol (2003) 0.80
Urodynamic differences between dysfunctional voiding and primary bladder neck obstruction in women. Urology (2012) 0.80
Voiding dysfunction in young, nulliparous women: symptoms and urodynamic findings. Int Urogynecol J Pelvic Floor Dysfunct (2004) 0.78
Long-term continence after surgery--what can we tell patients? J Urol (2012) 0.78
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology (2008) 0.78
Diagnosis and treatment of primary bladder neck obstruction in men. Curr Urol Rep (2005) 0.77
Comparison of urodynamic findings in women with anatomical versus functional bladder outlet obstruction. Female Pelvic Med Reconstr Surg (2013) 0.77
Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World J Urol (2014) 0.77
Can noninvasive evaluation of benign prostatic obstruction be optimized? Curr Opin Urol (2012) 0.77
Tolterodine for treatment of overactive bladder. Urol Clin North Am (2006) 0.76
Correlation of abdominal leak point pressure with objective incontinence severity in men with post-radical prostatectomy stress incontinence. Neurourol Urodyn (2005) 0.76
Endoscopic evacuation of Durasphere. Urology (2003) 0.76
Editorial comment. Urology (2011) 0.75
Reply: To PMID 24295256. Urology (2013) 0.75
Urodynamics for clinically suspected obstruction after anti-incontinence surgery in women. J Urol (2013) 0.75
Is There a Role for alpha-Blockers for the Treatment of Voiding Dysfunction Unrelated to Benign Prostatic Hyperplasia? Rev Urol (2005) 0.75
Editorial comment. Urology (2011) 0.75
Transdermal therapy for overactive bladder: present and future. Rev Urol (2003) 0.75
Fistulization between ectopic ureteral stump and uterus following nephroureterectomy: case report. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.75
Management of urinary retention and obstruction following surgery for stress urinary incontinence. Curr Urol Rep (2002) 0.75
Association between detrusor overactivity and postoperative outcomes in patients undergoing male bone anchored perineal sling. J Urol (2009) 0.75
Vaginal granulation tissue secondary to bone anchors: experience in two patients. J Urol (2003) 0.75
Urodynamic findings in women with insensible incontinence. Int J Urol (2012) 0.75
Pelvic floor reconstruction: state-of-the-art and beyond. Urol Clin North Am (2004) 0.75